KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics, Inc. (PVLA) Cash from Operations (2016 - 2022)

Palvella Therapeutics (PVLA) has disclosed Cash from Operations for 12 consecutive years, with 5353000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Operations fell 126.18% to 5353000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was 10800000.0, a 21.19% increase, with the full-year FY2024 number at 10800000.0, up 21.19% from a year prior.
  • Cash from Operations was 5353000.0 for Q4 2024 at Palvella Therapeutics, down from 2742000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 29906000.0 in Q2 2021 to a low of 22643000.0 in Q1 2022.
  • A 5-year average of 6899550.0 and a median of 10361000.0 in 2020 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: skyrocketed 405.85% in 2021, then tumbled 152.09% in 2022.
  • Palvella Therapeutics' Cash from Operations stood at 13417000.0 in 2020, then increased by 18.43% to 10944000.0 in 2021, then dropped by 18.17% to 12933000.0 in 2022, then skyrocketed by 258.1% to 20447000.0 in 2023, then tumbled by 126.18% to 5353000.0 in 2024.
  • Per Business Quant, the three most recent readings for PVLA's Cash from Operations are 5353000.0 (Q4 2024), 2742000.0 (Q3 2024), and 1603000.0 (Q2 2024).